Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-12

AUTHORS

Derek Weycker, Mark Hatfield, Aaron Grossman, Ahuva Hanau, Alex Lonshteyn, Anjali Sharma, David Chandler

ABSTRACT

BACKGROUND: Chemotherapy-induced thrombocytopenia (CIT) is a potentially serious complication that can lead to chemotherapy dose delays, dose reductions, or discontinuation, and increases the risk of serious bleeding events. The objectives of this study were to characterize the incidence, clinical consequences, and economic costs of CIT in current US clinical practice. METHODS: A retrospective cohort design and data from two US private healthcare claims repositories (01/2010-12/2016) were employed. Study population comprised adults who received selected myelosuppressive chemotherapy regimens for solid tumors or non-Hodgkin's lymphoma. CIT was identified based on: diagnosis code for thrombocytopenia or bleeding; procedure code for platelet transfusion or bleeding control; or drug code for thrombopoietin-receptor agonist. Incidence of CIT was evaluated during the chemotherapy course (max. no. cycles = 8), and associated consequences and costs (2016US$) were evaluated during the cycle of the CIT episode. RESULTS: Among 215,508 cancer chemotherapy patients, CIT incidence during the course (mean no. cycles = 4.6) was 9.7% (95% CI: 9.6-9.8), and ranged from 6.1% (5.9-6.3) for regimens containing cyclophosphamide to 13.5% (12.7-14.3) for regimens containing gemcitabine; among all patients, incidence was 2.7% (2.6-2.8) in cycle 1, 2.7% (2.6-2.8) in cycle 2, and 2.9% (2.9-3.0) in cycles thereafter. One-third of CIT episodes were managed in hospital, and for the subset of patients hospitalized with a first-listed diagnosis of CIT, mean length of stay was 4.6 (4.4-5.0) days and mean cost of inpatient care was $36,448 (32,332-41,331). Across cycles with CIT, mean cost of CIT-related care was $2179 (2029-2329), comprising $1024 (881-1167) for inpatient care and $1153 (1119-1187) for outpatient care. CONCLUSIONS: In this retrospective evaluation of cancer chemotherapy patients, CIT incidence was high, especially among patients receiving gemcitabine-based regimens, and the costs of CIT-related care were substantial. Accordingly, interventions aimed at identifying and targeting high-risk patients for preventative measures may yield substantial clinical and economic benefits. More... »

PAGES

151

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12885-019-5354-5

DOI

http://dx.doi.org/10.1186/s12885-019-5354-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1112138980

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30764783


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Policy Analysis (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418689.a", 
          "name": [
            "Policy Analysis Inc. (PAI), Four Davis Court, 02445, Brookline, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Weycker", 
        "givenName": "Derek", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amgen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "Amgen Inc., Thousand Oaks, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hatfield", 
        "givenName": "Mark", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Policy Analysis (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418689.a", 
          "name": [
            "Policy Analysis Inc. (PAI), Four Davis Court, 02445, Brookline, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Grossman", 
        "givenName": "Aaron", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Policy Analysis (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418689.a", 
          "name": [
            "Policy Analysis Inc. (PAI), Four Davis Court, 02445, Brookline, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hanau", 
        "givenName": "Ahuva", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Policy Analysis (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418689.a", 
          "name": [
            "Policy Analysis Inc. (PAI), Four Davis Court, 02445, Brookline, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lonshteyn", 
        "givenName": "Alex", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amgen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "Amgen Inc., Thousand Oaks, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sharma", 
        "givenName": "Anjali", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Amgen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "Amgen Inc., Thousand Oaks, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chandler", 
        "givenName": "David", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00520-016-3421-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000824919", 
          "https://doi.org/10.1007/s00520-016-3421-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00520-016-3421-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000824919", 
          "https://doi.org/10.1007/s00520-016-3421-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/11594310-000000000-00000", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001126297", 
          "https://doi.org/10.2165/11594310-000000000-00000"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.11195", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025451245"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1078155210380293", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035891731"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1078155210380293", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035891731"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1634/theoncologist.6-suppl_5-15", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045057412"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.critrevonc.2016.01.005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049943169"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.clinthera.2009.11.020", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052323610"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2001.19.4.1137", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074754836"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079084112", 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00277-017-2953-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084020456", 
          "https://doi.org/10.1007/s00277-017-2953-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00277-017-2953-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084020456", 
          "https://doi.org/10.1007/s00277-017-2953-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/03007995.2017.1386638", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092003429"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/03007995.2017.1386858", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092003430"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.18203/2349-3259.ijct20183376", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1105898620"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.18203/2349-3259.ijct20183376", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1105898620"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2018.36.15_suppl.e18911", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106717747"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2019-12", 
    "datePublishedReg": "2019-12-01", 
    "description": "BACKGROUND: Chemotherapy-induced thrombocytopenia (CIT) is a potentially serious complication that can lead to chemotherapy dose delays, dose reductions, or discontinuation, and increases the risk of serious bleeding events. The objectives of this study were to characterize the incidence, clinical consequences, and economic costs of CIT in current US clinical practice.\nMETHODS: A retrospective cohort design and data from two US private healthcare claims repositories (01/2010-12/2016) were employed. Study population comprised adults who received selected myelosuppressive chemotherapy regimens for solid tumors or non-Hodgkin's lymphoma. CIT was identified based on: diagnosis code for thrombocytopenia or bleeding; procedure code for platelet transfusion or bleeding control; or drug code for thrombopoietin-receptor agonist. Incidence of CIT was evaluated during the chemotherapy course (max. no. cycles\u2009=\u20098), and associated consequences and costs (2016US$) were evaluated during the cycle of the CIT episode.\nRESULTS: Among 215,508 cancer chemotherapy patients, CIT incidence during the course (mean no. cycles\u2009=\u20094.6) was 9.7% (95% CI: 9.6-9.8), and ranged from 6.1% (5.9-6.3) for regimens containing cyclophosphamide to 13.5% (12.7-14.3) for regimens containing gemcitabine; among all patients, incidence was 2.7% (2.6-2.8) in cycle 1, 2.7% (2.6-2.8) in cycle 2, and 2.9% (2.9-3.0) in cycles thereafter. One-third of CIT episodes were managed in hospital, and for the subset of patients hospitalized with a first-listed diagnosis of CIT, mean length of stay was 4.6 (4.4-5.0) days and mean cost of inpatient care was $36,448 (32,332-41,331). Across cycles with CIT, mean cost of CIT-related care was $2179 (2029-2329), comprising $1024 (881-1167) for inpatient care and $1153 (1119-1187) for outpatient care.\nCONCLUSIONS: In this retrospective evaluation of cancer chemotherapy patients, CIT incidence was high, especially among patients receiving gemcitabine-based regimens, and the costs of CIT-related care were substantial. Accordingly, interventions aimed at identifying and targeting high-risk patients for preventative measures may yield substantial clinical and economic benefits.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s12885-019-5354-5", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024632", 
        "issn": [
          "1471-2407"
        ], 
        "name": "BMC Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "19"
      }
    ], 
    "name": "Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice", 
    "pagination": "151", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "ff8c5f4ef7d8169d80e4a3b3836c31e2888c6f21be1cb41e6e029fa99499cad2"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30764783"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "100967800"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12885-019-5354-5"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1112138980"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12885-019-5354-5", 
      "https://app.dimensions.ai/details/publication/pub.1112138980"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T10:15", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000348_0000000348/records_54297_00000002.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs12885-019-5354-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12885-019-5354-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12885-019-5354-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12885-019-5354-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12885-019-5354-5'


 

This table displays all metadata directly associated to this object as RDF triples.

150 TRIPLES      21 PREDICATES      43 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12885-019-5354-5 schema:about anzsrc-for:11
2 anzsrc-for:1117
3 schema:author Nb7c71b9246a34f9d99bedd8892f4a170
4 schema:citation sg:pub.10.1007/s00277-017-2953-6
5 sg:pub.10.1007/s00520-016-3421-x
6 sg:pub.10.2165/11594310-000000000-00000
7 https://app.dimensions.ai/details/publication/pub.1079084112
8 https://doi.org/10.1002/cncr.11195
9 https://doi.org/10.1016/j.clinthera.2009.11.020
10 https://doi.org/10.1016/j.critrevonc.2016.01.005
11 https://doi.org/10.1080/03007995.2017.1386638
12 https://doi.org/10.1080/03007995.2017.1386858
13 https://doi.org/10.1177/1078155210380293
14 https://doi.org/10.1200/jco.2001.19.4.1137
15 https://doi.org/10.1200/jco.2018.36.15_suppl.e18911
16 https://doi.org/10.1634/theoncologist.6-suppl_5-15
17 https://doi.org/10.18203/2349-3259.ijct20183376
18 schema:datePublished 2019-12
19 schema:datePublishedReg 2019-12-01
20 schema:description BACKGROUND: Chemotherapy-induced thrombocytopenia (CIT) is a potentially serious complication that can lead to chemotherapy dose delays, dose reductions, or discontinuation, and increases the risk of serious bleeding events. The objectives of this study were to characterize the incidence, clinical consequences, and economic costs of CIT in current US clinical practice. METHODS: A retrospective cohort design and data from two US private healthcare claims repositories (01/2010-12/2016) were employed. Study population comprised adults who received selected myelosuppressive chemotherapy regimens for solid tumors or non-Hodgkin's lymphoma. CIT was identified based on: diagnosis code for thrombocytopenia or bleeding; procedure code for platelet transfusion or bleeding control; or drug code for thrombopoietin-receptor agonist. Incidence of CIT was evaluated during the chemotherapy course (max. no. cycles = 8), and associated consequences and costs (2016US$) were evaluated during the cycle of the CIT episode. RESULTS: Among 215,508 cancer chemotherapy patients, CIT incidence during the course (mean no. cycles = 4.6) was 9.7% (95% CI: 9.6-9.8), and ranged from 6.1% (5.9-6.3) for regimens containing cyclophosphamide to 13.5% (12.7-14.3) for regimens containing gemcitabine; among all patients, incidence was 2.7% (2.6-2.8) in cycle 1, 2.7% (2.6-2.8) in cycle 2, and 2.9% (2.9-3.0) in cycles thereafter. One-third of CIT episodes were managed in hospital, and for the subset of patients hospitalized with a first-listed diagnosis of CIT, mean length of stay was 4.6 (4.4-5.0) days and mean cost of inpatient care was $36,448 (32,332-41,331). Across cycles with CIT, mean cost of CIT-related care was $2179 (2029-2329), comprising $1024 (881-1167) for inpatient care and $1153 (1119-1187) for outpatient care. CONCLUSIONS: In this retrospective evaluation of cancer chemotherapy patients, CIT incidence was high, especially among patients receiving gemcitabine-based regimens, and the costs of CIT-related care were substantial. Accordingly, interventions aimed at identifying and targeting high-risk patients for preventative measures may yield substantial clinical and economic benefits.
21 schema:genre research_article
22 schema:inLanguage en
23 schema:isAccessibleForFree true
24 schema:isPartOf N19cca9124dc74a5ba407f512bf7ea5e3
25 N55de9705887b486da73cc06b8b2d4366
26 sg:journal.1024632
27 schema:name Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice
28 schema:pagination 151
29 schema:productId N118c90c4f0b8423a81132c0d65c6216a
30 N133340940d614580bdaf1ff57428d4da
31 N5981e4e294fb441cb8906dd4c8a8a672
32 N8cf7448b2d8343c5bd26d8f3ff021056
33 Ne411ed9774084710a2f14dc31c9106d8
34 schema:sameAs https://app.dimensions.ai/details/publication/pub.1112138980
35 https://doi.org/10.1186/s12885-019-5354-5
36 schema:sdDatePublished 2019-04-11T10:15
37 schema:sdLicense https://scigraph.springernature.com/explorer/license/
38 schema:sdPublisher Nbe4aec6feb9a43e5b13aed23a2c95839
39 schema:url https://link.springer.com/10.1186%2Fs12885-019-5354-5
40 sgo:license sg:explorer/license/
41 sgo:sdDataset articles
42 rdf:type schema:ScholarlyArticle
43 N09f29c96688941cd8eaeadaf2950ccb5 rdf:first Neb4fea80043a45e287b30a304196b15c
44 rdf:rest Nc05b99e3d3cb46db8566107e3b8c07ab
45 N118c90c4f0b8423a81132c0d65c6216a schema:name doi
46 schema:value 10.1186/s12885-019-5354-5
47 rdf:type schema:PropertyValue
48 N133340940d614580bdaf1ff57428d4da schema:name readcube_id
49 schema:value ff8c5f4ef7d8169d80e4a3b3836c31e2888c6f21be1cb41e6e029fa99499cad2
50 rdf:type schema:PropertyValue
51 N145547a2b37846e68e70694a939d90aa rdf:first N20208d8777014b6e82dc86286bfd5d14
52 rdf:rest rdf:nil
53 N19cca9124dc74a5ba407f512bf7ea5e3 schema:volumeNumber 19
54 rdf:type schema:PublicationVolume
55 N1fe559c5551e42b195042e3ab401e837 rdf:first N949a7d8f8be542f68b6dae44794d6132
56 rdf:rest N09f29c96688941cd8eaeadaf2950ccb5
57 N20208d8777014b6e82dc86286bfd5d14 schema:affiliation https://www.grid.ac/institutes/grid.417886.4
58 schema:familyName Chandler
59 schema:givenName David
60 rdf:type schema:Person
61 N3d6566b055ac41ed9cc62ffb7e36faee rdf:first N821a4a2313cb4d339a727026f2607bcf
62 rdf:rest N145547a2b37846e68e70694a939d90aa
63 N55de9705887b486da73cc06b8b2d4366 schema:issueNumber 1
64 rdf:type schema:PublicationIssue
65 N5981e4e294fb441cb8906dd4c8a8a672 schema:name pubmed_id
66 schema:value 30764783
67 rdf:type schema:PropertyValue
68 N5c440730090a4b4aa17df95def70d542 schema:affiliation https://www.grid.ac/institutes/grid.418689.a
69 schema:familyName Hanau
70 schema:givenName Ahuva
71 rdf:type schema:Person
72 N821a4a2313cb4d339a727026f2607bcf schema:affiliation https://www.grid.ac/institutes/grid.417886.4
73 schema:familyName Sharma
74 schema:givenName Anjali
75 rdf:type schema:Person
76 N8cf7448b2d8343c5bd26d8f3ff021056 schema:name nlm_unique_id
77 schema:value 100967800
78 rdf:type schema:PropertyValue
79 N949a7d8f8be542f68b6dae44794d6132 schema:affiliation https://www.grid.ac/institutes/grid.417886.4
80 schema:familyName Hatfield
81 schema:givenName Mark
82 rdf:type schema:Person
83 Nb7c71b9246a34f9d99bedd8892f4a170 rdf:first Nc765dfa5f6ac45948ed0c12fef49b06f
84 rdf:rest N1fe559c5551e42b195042e3ab401e837
85 Nbe4aec6feb9a43e5b13aed23a2c95839 schema:name Springer Nature - SN SciGraph project
86 rdf:type schema:Organization
87 Nc05b99e3d3cb46db8566107e3b8c07ab rdf:first N5c440730090a4b4aa17df95def70d542
88 rdf:rest Nf6e59ef0bede4160b9063c865e012ada
89 Nc765dfa5f6ac45948ed0c12fef49b06f schema:affiliation https://www.grid.ac/institutes/grid.418689.a
90 schema:familyName Weycker
91 schema:givenName Derek
92 rdf:type schema:Person
93 Ncbdac4a80dae4bf081d0bcb6bed4cbda schema:affiliation https://www.grid.ac/institutes/grid.418689.a
94 schema:familyName Lonshteyn
95 schema:givenName Alex
96 rdf:type schema:Person
97 Ne411ed9774084710a2f14dc31c9106d8 schema:name dimensions_id
98 schema:value pub.1112138980
99 rdf:type schema:PropertyValue
100 Neb4fea80043a45e287b30a304196b15c schema:affiliation https://www.grid.ac/institutes/grid.418689.a
101 schema:familyName Grossman
102 schema:givenName Aaron
103 rdf:type schema:Person
104 Nf6e59ef0bede4160b9063c865e012ada rdf:first Ncbdac4a80dae4bf081d0bcb6bed4cbda
105 rdf:rest N3d6566b055ac41ed9cc62ffb7e36faee
106 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
107 schema:name Medical and Health Sciences
108 rdf:type schema:DefinedTerm
109 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
110 schema:name Public Health and Health Services
111 rdf:type schema:DefinedTerm
112 sg:journal.1024632 schema:issn 1471-2407
113 schema:name BMC Cancer
114 rdf:type schema:Periodical
115 sg:pub.10.1007/s00277-017-2953-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084020456
116 https://doi.org/10.1007/s00277-017-2953-6
117 rdf:type schema:CreativeWork
118 sg:pub.10.1007/s00520-016-3421-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1000824919
119 https://doi.org/10.1007/s00520-016-3421-x
120 rdf:type schema:CreativeWork
121 sg:pub.10.2165/11594310-000000000-00000 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001126297
122 https://doi.org/10.2165/11594310-000000000-00000
123 rdf:type schema:CreativeWork
124 https://app.dimensions.ai/details/publication/pub.1079084112 schema:CreativeWork
125 https://doi.org/10.1002/cncr.11195 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025451245
126 rdf:type schema:CreativeWork
127 https://doi.org/10.1016/j.clinthera.2009.11.020 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052323610
128 rdf:type schema:CreativeWork
129 https://doi.org/10.1016/j.critrevonc.2016.01.005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049943169
130 rdf:type schema:CreativeWork
131 https://doi.org/10.1080/03007995.2017.1386638 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092003429
132 rdf:type schema:CreativeWork
133 https://doi.org/10.1080/03007995.2017.1386858 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092003430
134 rdf:type schema:CreativeWork
135 https://doi.org/10.1177/1078155210380293 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035891731
136 rdf:type schema:CreativeWork
137 https://doi.org/10.1200/jco.2001.19.4.1137 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074754836
138 rdf:type schema:CreativeWork
139 https://doi.org/10.1200/jco.2018.36.15_suppl.e18911 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106717747
140 rdf:type schema:CreativeWork
141 https://doi.org/10.1634/theoncologist.6-suppl_5-15 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045057412
142 rdf:type schema:CreativeWork
143 https://doi.org/10.18203/2349-3259.ijct20183376 schema:sameAs https://app.dimensions.ai/details/publication/pub.1105898620
144 rdf:type schema:CreativeWork
145 https://www.grid.ac/institutes/grid.417886.4 schema:alternateName Amgen (United States)
146 schema:name Amgen Inc., Thousand Oaks, CA, USA
147 rdf:type schema:Organization
148 https://www.grid.ac/institutes/grid.418689.a schema:alternateName Policy Analysis (United States)
149 schema:name Policy Analysis Inc. (PAI), Four Davis Court, 02445, Brookline, MA, USA
150 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...